AXL and melanoma: Up-regulation of the expression of EGF-R, PDGFRβ, AXL and IGF-1R in melanoma cells that have developed resistance to BRAF V600E targeted therapy [19–25] results in reactivation of the MAPK and the PI3K/AKT pathways.